Associations of anti-H. pylori IgG seropositivity with mediators. by Jing Wang (6206297)

Subjects:

Particle size distribution of GO-GA NPs. by Huda H. Elbehery (22492996)

“…The inclusion of GO-GA NPs at LC₄₀ had a significant post-effect on progeny production of <i><i>C. maculatus</i></i>, resulting in a significant reduction in the number of deposited eggs and adult emergence, which led to a significant decrease in the percentage of adult emergence to 15.23 ± 5.46 compared to 61.33 ± 2.94, as observed in the GO treatment. …”

GC-MS chromatogram of garlic essential oil. by Huda H. Elbehery (22492996)

“…The inclusion of GO-GA NPs at LC₄₀ had a significant post-effect on progeny production of <i><i>C. maculatus</i></i>, resulting in a significant reduction in the number of deposited eggs and adult emergence, which led to a significant decrease in the percentage of adult emergence to 15.23 ± 5.46 compared to 61.33 ± 2.94, as observed in the GO treatment. …”

Food intake in groups A, B and C. by Sohail Afzal (10850709)

“…Statistically, there was a significant decrease in EPG values from days 0–14. …”

Microstructure of various samples: (a) UT, (b) SP1, (c) SP2, and (d) SP3. by Huashen Guan (20454677)

Genetic evidence linking gastroesophageal reflux disease to chronic kidney disease and kidney failure: a two-step Mendelian randomization study by Fanghong Zheng (8931326)

“…Interventions with these factors could significantly decrease the burden of CKD attributable to GERD.…”

Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

Subjects:

Post-treatment CAPS score changes from clinical trials with off-label PTSD medications. by Filip Stanicic (17808254)

Subjects:

Analyses of directed phase lag index (dPLI [44]) for excitatory/inhibitory (E/I) ratios with respect to pyramidal (Pyr) and parvalbumin (PV) populations (<i>A</i>) and Pyr and soma... by Nobuhiko Wagatsuma (494052)

“…Values of dPLI from PV to Pyr and from SOM to Pyr populations for each trial are shown by small black and gray circles, respectively. <b><i>A.</i></b> Values of dPLI from PV or SOM inhibitory interneurons to Pyr neurons as a function of E/I ratio with respect to Pyr and PV populations. …”

IFA significantly attenuated capsule-mediated resistance to the binding of C3b and C5b-9 to bacterial surface. by Tingting Wang (123983)

Impact of 5′ nucleotidase disruption on <i>M</i>. <i>bovis</i> growth phenotype in axenic conditions. by Aga E. Gelgie (17661720)

Data set. by Belachew Tekleyohannes Wogayehu (19470257)

Subjects: